Oncolytics Biotech Inc. (ONCY)’s Financial Results Comparing With InflaRx N.V. (NASDAQ:IFRX)

Both Oncolytics Biotech Inc. (NASDAQ:ONCY) and InflaRx N.V. (NASDAQ:IFRX) are each other’s competitor in the Biotechnology industry. Thus the contrast of their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oncolytics Biotech Inc. N/A 0.00 N/A -0.84 0.00
InflaRx N.V. N/A 0.00 N/A -1.42 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Oncolytics Biotech Inc. and InflaRx N.V.


Table 2 represents Oncolytics Biotech Inc. (NASDAQ:ONCY) and InflaRx N.V. (NASDAQ:IFRX)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oncolytics Biotech Inc. 0.00% -205.3% -95.4%
InflaRx N.V. 0.00% -22.7% -21.9%


Oncolytics Biotech Inc.’s Current Ratio is 5.5 while its Quick Ratio is 5.5. On the competitive side is, InflaRx N.V. which has a 18.7 Current Ratio and a 18.7 Quick Ratio. InflaRx N.V. is better positioned to pay off short and long-term obligations compared to Oncolytics Biotech Inc.

Analyst Ratings

Oncolytics Biotech Inc. and InflaRx N.V. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Oncolytics Biotech Inc. 0 0 0 0.00
InflaRx N.V. 0 0 1 3.00

InflaRx N.V. on the other hand boasts of a $58 consensus target price and a 23.22% potential upside.

Institutional and Insider Ownership

The shares of both Oncolytics Biotech Inc. and InflaRx N.V. are owned by institutional investors at 2.5% and 58.4% respectively. Insiders held 1.8% of Oncolytics Biotech Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Oncolytics Biotech Inc. -8.18% -5.98% -25% -51.78% -66.09% 8.56%
InflaRx N.V. 16.4% 16.44% 25.22% 14.31% 39.39% 4.98%

For the past year Oncolytics Biotech Inc. was more bullish than InflaRx N.V.


InflaRx N.V. beats on 4 of the 6 factors Oncolytics Biotech Inc.

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was founded in 2007 and is headquartered in Jena, Germany.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.